Brookfield Reaffirms Its Interest in Grifols, Requests More Time for Analysis, Sources Say
LONDON – Brookfield (NYSE: BN), a Canadian fund, reaffirmed its interest in a potential takeover of Spanish drugmaker Grifols (NASDAQ: […]
Healthcare
Healthcare
Grifols (NASDAQ: GRFS) to Allocate $402 Million for New Industrial Centre: Report
Grifols (NASDAQ: GRFS), the Spanish drugmaker, plans to invest 360 million euros ($401.98 million) to build a new industrial plant
Grifols (NASDAQ: GRFS) to Allocate $402 Million for New Industrial Centre: Report Read More »
Biotech vs. Pharma Stocks: Which stock is better for investment?
Investing in the healthcare sector can be lucrative and complex, particularly in biotechnology (biotech) and pharmaceuticals (pharma). Both sectors offer
Biotech vs. Pharma Stocks: Which stock is better for investment? Read More »
US FDA Greenlights GE HealthCare’s Diagnostic Drug for Heart Disease
The U.S. Food and Drug Administration approved GE HealthCare’s (NASDAQ: GEHC) diagnostic drug for use in the detection of coronary
US FDA Greenlights GE HealthCare’s Diagnostic Drug for Heart Disease Read More »
Haleon (NYSE: HLN) to Raise Stake in China JV
Haleon (NYSE: HLN) plans to increase its stake in its Chinese joint venture to 88% from 55%, the British consumer
EU Regulator Recommends Suspension of Pfizer’s Sickle Cell Disease Treatment
On Thursday, the European Medicines Agency (EMA) recommended suspending the marketing authorization for Pfizer’s (NYSE: PFE) sickle cell disease drug
EU Regulator Recommends Suspension of Pfizer’s Sickle Cell Disease Treatment Read More »
Analysts Say Pfizer’s Oxbryta Exit Could Speed Up Trials for Rival Sickle Cell Drugs
Pfizer’s (NYSE: PFE) decision late on Wednesday to withdraw its sickle cell disease treatment due to the risk of death
Analysts Say Pfizer’s Oxbryta Exit Could Speed Up Trials for Rival Sickle Cell Drugs Read More »
Evotec and Novo Nordisk (NYSE: NVO) Form Technology Development Partnership for Stem Cell Therapies
Evotec (NASDAQ: EVO), the German drug and development company, has entered into a technology development partnership with Novo Nordisk (NYSE:
Pfizer vs. Moderna: COVID Vaccine Patents Battle to Go to Appeal in UK
LONDON – Pfizer (NYSE: PFE) and Moderna’s (NASDAQ: MRNA) legal battle over their rival COVID-19 vaccines will continue after London’s
Pfizer vs. Moderna: COVID Vaccine Patents Battle to Go to Appeal in UK Read More »
Healthcare
2seventy Bio (NASDAQ: TSVT) Discontinues Enrollment in Key Blood Cancer Therapy Trial
2seventy Bio (NASDAQ: TSVT) will discontinue enrolling patients in a late-stage study of its cell therapy Abecma, developed in partnership
2seventy Bio (NASDAQ: TSVT) Discontinues Enrollment in Key Blood Cancer Therapy Trial Read More »
BioAge Labs Plans Upsized US IPO, Eyes Valuation of Nearly $640 Million
BioAge Labs is eyeing a valuation of up to $639.7 million in its upsized initial public offering in the United
BioAge Labs Plans Upsized US IPO, Eyes Valuation of Nearly $640 Million Read More »
Sanofi Receives Two Bids Valuing Its Consumer Health Unit at Around $17 Billion: Bloomberg
Sanofi (NASDAQ: SNY) has received two separate bids from private equity firms for its consumer health unit, which could be
US Senator Sanders Says Middlemen Won’t Punish Novo Nordisk If It Cuts Weight-Loss Drug Prices
WASHINGTON – On Tuesday, U.S. Senator Bernie Sanders said he had commitments from the nation’s top pharmacy benefit managers that
Sanofi (NASDAQ: SNY) CEO Believes New Drugs Will Drive Company Growth
NEW YORK – Sanofi’s (NASDAQ: SNY) chief executive, Paul Hudson, said in an interview on Monday that the company is
Sanofi (NASDAQ: SNY) CEO Believes New Drugs Will Drive Company Growth Read More »
Novo Nordisk (NYSE: NVO) Faces US Congressional Grilling Over Weight Loss Drug Pricing, FT Reports
Novo Nordisk’s (NYSE: NVO) chief executive is preparing for a showdown next week with U.S. Senator Bernie Sanders over the
Sanofi (NASDAQ: SNY) Secures FDA Approval for Multiple Myeloma Drug in Newly Diagnosed Patients
On Friday, the U.S. Food and Drug Administration said it has approved the use of a drug combination along with
Johnson & Johnson (NYSE: JNJ) Subsidiary Files for Bankruptcy to Advance $10 Billion Talc Settlement
A Johnson & Johnson (NYSE: JNJ) subsidiary filed for bankruptcy for a third time on Friday as the healthcare giant
US FTC Sues Pharmacy Benefit Managers for Inflated Insulin Prices
The U.S. Federal Trade Commission sued the country’s three largest pharmacy benefit managers on Friday, accusing them of steering diabetes
US FTC Sues Pharmacy Benefit Managers for Inflated Insulin Prices Read More »
US Appeals Court Revives Lawsuit Challenging Drug Price Negotiation Program
On Friday, a U.S. appeals court revived a lawsuit by healthcare and drug industry groups challenging the first-ever U.S. law
US Appeals Court Revives Lawsuit Challenging Drug Price Negotiation Program Read More »
Sanofi (NASDAQ: SNY) Reports Key Milestone in Multiple Sclerosis Drug Development
FRANKFURT – On Friday, Sanofi (NASDAQ: SNY) said that its multiple sclerosis drug candidate was shown to delay the worsening
Sanofi (NASDAQ: SNY) Reports Key Milestone in Multiple Sclerosis Drug Development Read More »
EU Regulator Approves Novo’s Wegovy for Obesity-Related Heart Condition
The European Medicines Agency backed the use of Novo Nordisk’s (NYSE: NVO) popular drug Wegovy to help ease heart failure
EU Regulator Approves Novo’s Wegovy for Obesity-Related Heart Condition Read More »
UnitedHealth Tech Unit’s Rivals Say New, Post-Hack Customers Are Staying
Smaller rivals to UnitedHealth’s tech unit Change Healthcare say they are signing longer-term contracts with hospitals and other customers who
UnitedHealth Tech Unit’s Rivals Say New, Post-Hack Customers Are Staying Read More »
Hims & Hers (NYSE: HIMS) Offers Compounded Wegovy for $99/Month to Select Professions
NEW YORK – On Wednesday, Hims & Hers Health (NYSE: HIMS), the U.S. telehealth company, said it will sell compounded
Hims & Hers (NYSE: HIMS) Offers Compounded Wegovy for $99/Month to Select Professions Read More »
GSK (NYSE: GSK) Settles Two California Lawsuits Over Heartburn Drug Zantac
On Wednesday, GSK (NYSE: GSK), the British drugmaker, said it had agreed to settle two lawsuits in California that claimed
GSK (NYSE: GSK) Settles Two California Lawsuits Over Heartburn Drug Zantac Read More »
